Literature DB >> 2070136

Inflammatory cells in graft-versus-host disease on the rectum: immunopathologic analysis.

S A Weisdorf1, J Roy, D Snover, J L Platt, D J Weisdorf.   

Abstract

The inflammatory infiltrate of acute rectal graft-versus-host disease (GVHD) was investigated by indirect immunofluorescence. Twenty biopsies from 11 allogeneic bone marrow transplant recipients were studied in four groups: biopsies before transplantation; biopsies after transplantation without GVHD; biopsies from patients with extra-intestinal GVHD only; and biopsies from patients with intestinal GVHD. Total T cell numbers (CD2+, CD3+) in the lamina propria differed little in the four groups. CD4+ lymphocytes appeared to be decreased in GVHD while CD8+ lymphocytes were significantly increased (p less than 0.01), thus significantly lowering the CD4/CD8 ratio. In pre-transplant patients and in those without GVHD this ratio resembled that in normal peripheral blood (1.44 +/- 0.5 and 2.46 +/- 1.3, respectively) but was significantly lower in both extraintestinal (0.71 +/- 0.08) and intestinal GVHD (0.56 +/- 0.08) (p less than 0.05). Acute intestinal GVHD was marked by a fourfold increase in CD57+ lymphoid cells within the epithelium and the lamina propria (p less than 0.05). The recognition of CD57+ cells, which may include natural killer-like cells, within rectal lymphoid infiltrates suggests a possible role for non-HLA restricted effector cells in GVHD of the rectum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070136

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Immunohistochemical changes in sigmoid colon after allogeneic and autologous bone marrow transplantation.

Authors:  G M Forbes; W N Erber; R P Herrmann; J M Davies; B J Collins
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

2.  Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease.

Authors:  K Landfried; F Bataille; G Rogler; J Brenmoehl; K Kosovac; D Wolff; I Hilgendorf; J Hahn; M Edinger; P Hoffmann; F Obermeier; J Schoelmerich; R Andreesen; E Holler
Journal:  Clin Exp Immunol       Date:  2009-11-11       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.